MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) requires refined risk stratification tools to drive decisions concerning effective therapeutic strategies. Here, genome-wide screening was carried out for identifying miRNA molecules capable of predicting treatment outcome in AML patients based on the TCGA dataset. We id...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Mingshan, Zhang, Ninghan, Wang, Rong, Shao, Tingting, Feng, Yuan, Shen, Yangling, Liu, Xuejiao, Zhao, Kai, Zhu, Shengyun, Xu, Linyan, Yao, Yao, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798954/
https://www.ncbi.nlm.nih.gov/pubmed/31681594
http://dx.doi.org/10.3389/fonc.2019.01058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798954/
https://www.ncbi.nlm.nih.gov/pubmed/31681594
http://dx.doi.org/10.3389/fonc.2019.01058

Ejemplares similares